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Epigallocatechin 3-gallate applications on HT-29 and MCF-7 cell lines and
evaluation of tumor suppressor gene methylation
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Abstract: Epigallocatechin 3-gallate (EGCG) is an antitumor molecule and shows this activity by binding to the active center of a
methyltransferase enzyme (DNMT1). The methylation of DNA sequences of tumor suppressor and DNA repair genes is observed in
different stages of carcinogenesis. In this study, we analyzed the effect of EGCG on the methylation status of 25 tumor suppressor genes
in cancer cell lines HT-29 and MCF-7. HT-29 and MCF-7 cells were incubated with 10 µM, 20 µM, and 50 µM and 1 µM, 5 µM, and 10
µM EGCG for 48 h, respectively. We found promoter hypermethylation of (1) CDH13, GATA5, and RARβ genes in MCF-7 cell line and
(2) RARβ, ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5 genes in HT-29 cell line. However, (3) after EGCG application, no
changes in methylation status were detected in our samples. Our results suggest that methylation status of tumor suppressor genes did
not change with different EGCG doses.
Key words: Epigallocatechin 3-gallate, epigenetics, methylation, breast cancer, colorectal cancer

1. Introduction
EGCG is the major component of catechins found in green
tea and exists in four active forms: (1)-epigallocatechin3-gallate
(EGCG),
(2)-epigallocatechin
(EGC),
(3)-epicatechin-3-gallate (ECG), and (4)-epicatechin (EC)
(Zeng et al., 2014). Catechins, which are polyphenols,
constitute nearly 30%–40% of the dry weight of green tea
(Lecumberri et al., 2013; Zeng et al., 2014), which is one
of the most popular beverages in the world, after water.
EGCG is an important compound, as it has antitumor
activity. It exerts this activity by binding to the active
center of DNA methyltransferase-1 (DNMT1) enzyme, as
previously demonstrated by in vitro activity assays (Lee et
al., 2005; Pandey et al., 2010). Thus, it is involved in the
changes in gene expression by an epigenetic mechanism
decreasing DNA hypermethylation and is a potential
anticancer drug for cancer prevention or treatment (Fang
et al., 2003; Chen et al., 2011).
Cancer development and progression is a multistep
process evolving through both genetic and epigenetic
mechanisms. The loss of function of tumor suppressor
genes is a fundamental step that is quite well known in
cancer development. Aberrant promoter methylation,
especially hypermethylation of tumor suppressor genes, is
an important mechanism of epigenetic silencing (Baylin
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and Herman, 2000; Brooks, 2009; Nystrom and Mutanen,
2009; Arends, 2013). Nearly half of all known tumor
suppressor genes might be inactivated by hypermethylation
(Arai et al., 2006).
Breast and colorectal cancers are common cancers and
constitute a major public health problem; thus, they are
important targets for research and the implementation of
treatment (Cho et al., 2010; Colussi et al., 2013). It has been
reported that CpG island methylation of tumor-related
genes is an important event in both the pre-invasive and
progression stages of breast cancer (Park et al., 2011).
Colorectal cancer is another common cause of morbidity
and mortality, and dietary components play an important
role in the pathogenesis and, therefore, prevention of this
cancer (Singh and Fraser, 1998). In recent years, specific
nutritional components, such as catechins, have been
reported to be bioactive molecules acting on cancer cells
(Fang et al., 2003; Li and Tollefsbol, 2010; Nandakumar et
al., 2011).
In this study, considering (1) EGCG is a potential
anticancer drug, (2) it binds to DNA methyltransferase
enzyme, (3) promoter methylation of tumor suppressor
genes is an important mechanism of epigenetic
silencing, and (4) epigenetic silencing is important to the
carcinogenesis of adenocarcinomas, we aimed to evaluate
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the effects of EGCG on the methylation status of 25 tumor
suppressor gene promoters in colorectal (HT-29) and
breast cancer (MCF-7) cell lines. Methylation-specific
multiplex ligation probe amplification (MS-MLPA) was
used for the analysis that determines both the methylation
status of genes of interest and the copy number changes.
We tested the effects of different EGCG concentrations on
the methylation status of tumor suppressor gene promoters
in HT-29 and MCF-7 cell lines and also assayed effects of
these application concentrations on cell proliferation.
2. Materials and methods
2.1. Cell lines
Human colon adenocarcinoma (designation: HT-29, ATCC
number: HTB-38) and human breast adenocarcinoma
(designation: MCF-7, ATCC number: HTB-22) cell lines
were obtained from the American Type Tissue Culture
Collection (ATCC). Cells were cultured in RPMI 1640
supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, penicillin (100 IU/mL), and streptomycin
(100 μg/mL) (media and serums from Biochrom AG,
Berlin, Germany). All cells were cultured at 37 °C in the
humidified atmosphere of a 5% CO2 incubator (Heraeus,
Hanau, Germany).
2.2. EGCG treatment
Commercially available (−)-epigallocatechin gallate was
used in the experiments (Sigma-Aldrich, St Louis, MO,
USA). Powdered EGCG was dissolved in water to prepare
5 mg/mL stock solution and stored at –20 °C. For each cell
line (MCF-7 and HT-29), 2 million cells were transferred
to 9 different 25 cm2 tissue culture flasks. Three of these
flasks were assigned as the control group, and EGCG was
not applied to these flasks. The other 6 flasks were used in
duplicate for EGCG application. HT-29 and MCF-7 cells
were incubated with 10 µM, 20 µM, and 50 µM (Zhang,
2012) and 1 µM, 5 µM, and 10 µM (Lee et al., 2005; Hsu
et al., 2011) EGCG, respectively for 48 h, as defined by
previous studies. At the end of 48 h for all groups, DNA
samples were extracted from both untreated control
cells and EGCG-treated cells by using QIAamp DNA
mini kit (Qiagen, Carlsbad, Germany), according to the
manufacturer’s instructions.
2.3. MS-MLPA analysis
SALSA MLPA kit ME002-B1 Tumor Suppressor 2 kit
(MRC Holland, Amsterdam, the Netherlands) was
utilized to analyze the methylation status of promoter
regions of 25 different tumor suppressor genes (Table).
MLPA reactions were performed according to the
manufacturer’s instructions. Briefly, 250 ng of genomic
DNA extracted from control and EGCG applied cell
lines in 5 µL of TE buffer (10 mM Tris-HCl, pH 8.2; 0.1
mM EDTA) was denatured. Oligonucleotide probes were
hybridized to the genomic DNA for 16 h. Following the

hybridization reaction, hybridized probes were ligated
via ligation reaction. All reaction tubes were divided into
two tubes, one for copy number analyses and the second
for methylation analyses. To determine the methylation
status of the promoter regions, a restriction endonuclease
reaction was performed by using HhaI enzyme. As a
methylation-sensitive restriction endonuclease, HhaI can
only digest an unmethylated DNA target. Following HhaI
digestion, PCR reaction was performed in all tubes. PCR
products were denatured and loaded onto an ABI 3500
capillary electrophoresis system (Applied Biosystems,
Foster City, CA, USA). Band analysis was performed
by GeneMapper software (Applied Biosystems), and
Coffalyser Net program (MRC Holland) was used to
determine copy number analysis and methylation status of
the EGCG-treated and untreated samples. The assay uses
14 reference probes (Figures 1 and 2; last 14 data points).
The undigested PCR runs were analyzed to obtain the copy
number ratio in samples. The ratios were calculated by
dividing the peak area obtained from each PCR reaction
by the sum of the area of reference probes (Figures 1A and
2A). Fragment analysis of digested samples was performed
to determine unmethylated regions. Since reference probes
do not have HhaI restriction sites, the total of peak area
values obtained from reference probes served as controls
to methylated regions that were not digested by the
enzyme. The methylation ratio was obtained by dividing
each digested probe’s peak area by the sum of the area of
reference probe peaks (Figures 1B and 2B). Differences in
methylation status between EGCG-treated and untreated
cells were compared using independent samples t-test.
SPSS version 20.0 (IBM Corp., Armonk, NY, USA) was
used for statistical analysis, and P < 0.05 was considered
significant.
2.4. Assay for cell proliferation
The effects of EGCG application on the proliferation
of MCF-7 and HT-29 cells were colorimetrically tested
by biochemical reduction of MTT (3-(4,5-dimethyl-2thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide)
(Sigma-Aldrich). Briefly, EGCG was serially diluted in half
from 400 to 1 µM in 96-well microtiter plate rows, except
for the untreated cells and medium control wells. Plates
were incubated for 48 h. The inhibition of cell proliferation
was determined after 4 h of incubation with 20 µL of MTT
(5 mg/mL). The optical density of the sodium dodecyl
sulfate (10%) (Sigma-Aldrich) solubilized tetrazolium salt
was measured at 540 nm with an ELISA reader (Biotek
Instrument ELx800, Winooski, VT, USA). Inhibition of
cell proliferation and inhibitory concentration 50 (IC50)
values (EGCG concentrations at which 50% of cells are
viable) were calculated from the logarithmic trend lines
of the proliferation versus EGCG concentration graphs.
Data of the triplicate experiments are expressed as mean ±
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Table. List of the tumor suppressor genes in which the methylation status of promoter regions was analyzed. Genes are listed according
to their chromosomal locations and nominated using the Universal Protein Resource (UniProt) catalog of information on proteins
(http://www.uniprot.org).
UniProt number

Gene alias

Gene name

Chromosomal location

Q15350

TP73

Tumor protein p73

1p36.32

P52701

MSH6

DNA mismatch repair protein

2p16.3

P10826

RARB

Retinoic acid receptor beta

3p24.2

P40337

VHL

Von Hippel–Lindau disease tumor suppressor

3p25.3

P03372

ESR1

Estrogen receptor

6q25.1

Q02548

PAX5

Paired box protein

9p13.2

P42771

CDKN2A

Cyclin-dependent kinase inhibitor 2A

9p21.3

B2CW77

KLLN

Killin

10q23.31

P16455

MGMT

Methylated-DNA--protein-cysteine methyltransferase

10q26.3

P16070

CD44

CD44 antigen

11p13

P26367

PAX6

Paired box protein

11p13

P19544

WT1

Wilms tumor protein

11p13

P09211

GSTP1

Glutathione S-transferase P

11q13.2

Q13315

ATM

Serine-protein kinase

11q22.3

Q9BY67

CADM1

Cell adhesion molecule 1

11q23.3

Q96EP1

CHFR

E3 ubiquitin-protein ligase

12q24.33

P51587

BRCA2

Breast cancer type 2 susceptibility protein

13q13.1

P06400

RB1

Retinoblastoma-associated protein

13q14.2

P07996

THBS1

Thrombospondin-1

15q14

Q9ULZ3

PYCARD

Apoptosis-associated speck-like protein containing a CARD

16p11.2

R55290

CDH13

Cadherin-13

16q23.3

P38398

BRCA1

Breast cancer type 1 susceptibility protein

17q21.31

P04637

TP53

Cellular tumor antigen p53

17p13.1

Q15831

STK11

Serine/threonine-protein kinase

19p13.3

Q9BWX5

GATA5

Transcription factor

20q13.33

standard error of means (SE). Differences in IC50 between
cell lines were statistically evaluated by independent
samples t-test at the 0.05 level using SPSS version 20.0
(IBM Corp., USA).
3. Results
3.1. Effects of EGCG on the methylation status of tumor
suppressor genes in MCF-7 and HT-29
Copy number analysis of the undigested (Figures 1A and
1B) MCF-7 and HT-29 samples demonstrated that 25
tumor suppressor genes (Table) had neither duplications
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nor deletions in their promoter regions. Similarly, there
were no changes in the copy numbers of the EGCG-treated
samples. Methylation status of the promoter regions of 25
tumor suppressor genes was detected by fragment analysis
of HhaI-digested samples. Each digested probe’s peak area
was divided by the combined peak areas of the control
probes lacking a HhaI restriction site, and methylation
ratios were obtained (Figures 1B and 2B). Accordingly,
promoter regions of CDH13, GATA5, and RARβ genes
were found to be hypermethylated in all samples from the
MCF-7 cell line, either EGCG-treated or untreated (Figure
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Figure 1. Methylation-specific MLPA analysis of MCF-7 cells. X-axis shows tumor suppressor genes (1–25) and reference
probes (26–40). Y-axis represents (A) copy number analysis of the tumor suppressor genes and (B) methylation profile of the
tumor suppressor genes with respect to reference probes. The red line and blue line in panel A represent minimum normalized
ratio with deletions and maximum normalized ratio with duplications in the regions, respectively. The red line and blue line in
panel B represent minimum normalized ratio of unmethylated promoter regions and maximum normalized ratio of methylated
regions, respectively. Promoter regions of CDH13, GATA5, and RARβ genes were hypermethylated in MCF-7 cell line.

1B). However, we did not detect a statistically significant
difference between treated and untreated groups. RARβ,
ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5
genes were hypermethylated in the HT-29 cell line in
addition to these three genes (Figure 2B). However, we did
not detect changes in methylation status in our samples in
HT-29 after EGCG application.
3.2. Antiproliferative effects of EGCG on MCF-7 and
HT-29 cells
MTT analysis revealed a concentration-dependent growth
inhibition by EGCG in both cell lines (Figure 3). IC50 was
11.2 ± 1.4 µM for MCF-7 cells, whereas it was 136.3 ± 2.1
µM for HT-29 cells. MTT results demonstrated that EGCG
caused significantly (P < 0.05) higher cytotoxicity in MCF7 cells compared to HT-29 cells. Next, we calculated
the effect of application concentrations on cell viability.

Viability of MCF-7 cells was 91.5 ± 1%, 65.3 ± 3.4%, and
52.0 ± 3.0% at 1, 5, and 10 µM EGCG concentrations,
respectively. Similarly, viability of HT-29 cells was 93.2 ±
1%, 88.7 ± 0.9%, and 77.7 ± 1.9% at 10, 20, and 50 µM
EGCG concentrations, respectively.
4. Discussion
Dietary components may play key roles in influencing
DNA methylation status, resulting in regulation of gene
expression. As cancer is a multistep process, gene activation
and silencing throughout epigenetic mechanisms, as well
as gene mutations, play important roles in carcinogenesis.
In recent years, dietary components have been widely
studied, and their potential use in cancer treatment and
prevention strategies has been discussed (Li and Tollefsboy,
2010; Hardy and Tollefsbol, 2011).
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h. Cell proliferation data are expressed as the percentage of untreated cell controls.
EGCG was more cytotoxic to MCF-7 cells (blue line) than HT-29 cells (red
line). Error bars represent standard error of means obtained from independent
triplicates.
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Figure 2. Methylation-specific MLPA analysis of HT-29 cells. X-axis shows tumor suppressor genes (1–25) and reference
probes (26–40). Y-axis shows (A) copy number analysis of the tumor suppressor genes and (B) methylation profile of the
tumor suppressor genes with respect to reference probes. The red line and blue line in panel A represent minimum normalized
ratio with deletions and maximum normalized ratio with duplications in the regions, respectively. The red line and blue
line in panel B represent minimum normalized ratio of unmethylated promoter regions and maximum normalized ratio of
methylated regions, respectively. Promoter regions of RARβ, ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5 genes
were hypermethylated in HT-29 cell line.
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Promoter methylation is an important epigenetic
change in cancer progression (Nystrom and Mutanen,
2009). We found that CDH13, GATA5, and RARβ genes
are methylated in the MCF-7 cell line: in addition to these
genes, ESR1, PAX6, WT1, CADM1, and CHFR were also
hypermethylated in HT-29 cell line. EGCG is known to
be an inhibitor of DNMT1 enzyme activity. It has also
been reported to be a chromatin remodeling agent (Li
and Tollefsboy, 2010). Whenever EGCG inhibits DNMT1
enzyme activity or affects chromatin remodeling in the
promoter region of a gene, changes in gene expression
occur, resulting in reactivation, as in the case of tumor
suppressor genes. In this study, we investigated the
demethylation effect of EGCG on the promoters of tumor
suppressor genes in MCF-7 and HT-29 cell lines.
Different EGCG concentrations did not change the
methylation status of the promoter regions, suggesting
that it has no demethylating effect on the cell lines
studied. Various factors including target availability,
intracellular bioavailability dependent on cellular uptake,
biotransformation or efflux, and EGCG application
concentration might contribute to the present results obtained
from cells of different histological origin. Meanwhile, the
presence or abundance of other DNA methyltransferases
(DNMT3a and DNMT3b) might influence the demethylating
effect of EGCG on these cell lines via DNMT1. It should be
noted that DNMT1 activity assays using nuclear extracts
and analysis of gene expression levels are needed for broader
conclusions. Results of the present study demonstrated that
EGCG was more cytotoxic to MCF-7 cells than HT-29,
i.e. IC50 was approximately 10-fold higher in MCF-7 cells.
Differences in intracellular signaling pathways between
HT-29 and MCF-7 cells may affect the cytotoxic potency
of EGCG since it binds to EGFR and PDGFR (Liang et al.,
1997; Sachinidis et al., 2000) and inhibits protein kinases
(Chung et al., 1999, 2001). When studying cells of different
histological origin, cytotoxic variations in response to test
materials should be considered. We investigated the effect
of EGCG on cell viability at different doses and found that
the range of cell viability after all EGCG concentrations

tested was 50%–92% and 78%–93% in MCF-7 and HT-29
cell lines, respectively. However, we did not observe any
changes in the DNA methylation status in the two cell lines
after application of specified doses of EGCG. We conclude
that the possible reasons are incubation doses that are below
the DNMT1 inhibitory concentration or cell lines that are
resistant to epigenetic effects of EGCG. In fact, according
to previously reported data, nontoxic concentrations (<15%
cell inhibition) of EGCG and catechin partially inhibited the
methylation status of the promoter regions of the RARb gene
(Lee et al., 2005) in breast cancer cells. In order to assess
whether sublethal EGCG treatment may have caused the
lack of demethylating effect on the cell lines tested, we also
performed MS-MLPA analysis of MCF-7 cells treated with
50 and 100 µM EGCG, at which 8% and 4% cell viability was
attained, respectively. Similar to the results demonstrated,
we did not observe any significant changes in the DNA
methylation status of the treated cells at these concentrations
(data not shown).
EGCG is transported into the cell by passive
diffusion and converted to the methylated metabolites
and glucuronides. However, EGCG is pumped out by
multidrug resistance-associated proteins (MRPs), as
evidenced by increased EGCG accumulation in HT-29
cells in the presence of the MRP inhibitors indomethacin
and probenecid (Hong et al., 2002). Both HT-29 and MCF7 cells were found to express MRP1 (Alvarez et al., 1998;
Kars et al., 2006).
In conclusion, although our study did not support the
hypothesis that EGCG intake in early stages of colorectal
and breast cancers could be preventive, especially when
the importance of consuming dietary products in these
tumors is taken into consideration, further studies could
be designed on this basis with early-stage and numerous
cancer cell lines.
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